Medtech Convergence Fund
SV Health Investors is a transatlantic healthcare-focused investment manager investing across therapeutics, medtech and healthcare growth. The firm supports company creation and early- through growth-stage investments, manages specialized funds (including the Dementia Discovery Fund and Medtech Convergence Fund), provides active portfolio management and syndicates strategic partners to advance clinical and commercial development of healthcare innovations.
Medtech Convergence Fund
Boston, Massachusetts, United States, North America
Services
Equity investment (Therapeutics, Medtech, Healthcare Growth)
Provides funding across the lifecycle including company formation, seed and biotech funds, growth equity (minority growth capital), recapitalizations, buyouts and acquisitions. SV often serves as lead or co-lead and takes board seats.
Company creation and early-stage portfolio development
Founding new companies and making early-stage investments to capture significant equity positions and influence strategy, including targeted activity in neurodegeneration/dementia via the Dementia Discovery Fund.
Strategic and operational support (Operating Partners & Executive in Residence)
Provides operating executives, operating partners and an Executive in Residence program to support portfolio company strategy, commercialization and scaling.
Syndication and strategic partnerships
Structures co-investments and fund-level strategic LP relationships with pharmaceutical companies, foundations and corporate partners to provide additional capital and domain expertise.
ESG, impact measurement and investor relations
Tracks governance, social and environmental metrics for portfolio companies, produces impact/ESG reporting and provides investor relations support and fundraising coordination.
Equity investment (Therapeutics, Medtech, Healthcare Growth)
Provides funding across the lifecycle including company formation, seed and biotech funds, growth equity (minority growth capital), recapitalizations, buyouts and acquisitions. SV often serves as lead or co-lead and takes board seats.
Company creation and early-stage portfolio development
Founding new companies and making early-stage investments to capture significant equity positions and influence strategy, including targeted activity in neurodegeneration/dementia via the Dementia Discovery Fund.
Strategic and operational support (Operating Partners & Executive in Residence)
Provides operating executives, operating partners and an Executive in Residence program to support portfolio company strategy, commercialization and scaling.
Syndication and strategic partnerships
Structures co-investments and fund-level strategic LP relationships with pharmaceutical companies, foundations and corporate partners to provide additional capital and domain expertise.
ESG, impact measurement and investor relations
Tracks governance, social and environmental metrics for portfolio companies, produces impact/ESG reporting and provides investor relations support and fundraising coordination.
Portfolio
Acquired by AdaptHealth in a transaction with total consideration including approximately $1.1 billion cash plus stock; SV listed as a shareholder and investor in the transaction.
#Healthcare Growth
Completed an oversubscribed US$112M Series C financing co-led by SV Health Investors (3 Feb 2025). SV partner Jamil M. Beg joined the board in connection with the financing. AdvanCell expanded a strategic collaboration with Eli Lilly (10 Feb 2025) to research and develop Pb-212-based targeted alpha therapies. AdvanCell describes capabilities in Pb-212 production and radiopharmaceutical manufacturing; company press contact listed as Andrew Adamovich, CEO (contact@advancell.com.au; +61 2 8000 4199).
#Therapeutics / Radiopharmaceuticals
Raised $29M Series A-3 with participation from SV’s Medtech Convergence Fund; product is an AI-enabled wearable and monitoring platform for senior care.
#Medtech (AI-enabled senior care)
Closed $100.5M Series B financing with SV Health Investors joining the syndicate (March 2020); SV partner Mike Ross joined the company board in connection with the round.
#Therapeutics (Oncology / Immuno-oncology)
Reported acquisition by MSD (Merck) for up to $3 billion (29 May 2024).
#Therapeutics (Ophthalmology)
Platform company with multiple partnership and licensing arrangements referenced in SV news items.
#Biotech / Discovery platform
Acquired by AdaptHealth in a transaction with total consideration including approximately $1.1 billion cash plus stock; SV listed as a shareholder and investor in the transaction.
#Healthcare Growth
Completed an oversubscribed US$112M Series C financing co-led by SV Health Investors (3 Feb 2025). SV partner Jamil M. Beg joined the board in connection with the financing. AdvanCell expanded a strategic collaboration with Eli Lilly (10 Feb 2025) to research and develop Pb-212-based targeted alpha therapies. AdvanCell describes capabilities in Pb-212 production and radiopharmaceutical manufacturing; company press contact listed as Andrew Adamovich, CEO (contact@advancell.com.au; +61 2 8000 4199).
#Therapeutics / Radiopharmaceuticals
Raised $29M Series A-3 with participation from SV’s Medtech Convergence Fund; product is an AI-enabled wearable and monitoring platform for senior care.
#Medtech (AI-enabled senior care)
Closed $100.5M Series B financing with SV Health Investors joining the syndicate (March 2020); SV partner Mike Ross joined the company board in connection with the round.
#Therapeutics (Oncology / Immuno-oncology)
Reported acquisition by MSD (Merck) for up to $3 billion (29 May 2024).
#Therapeutics (Ophthalmology)
Platform company with multiple partnership and licensing arrangements referenced in SV news items.
#Biotech / Discovery platform